Patents by Inventor Claudio Sustmann
Claudio Sustmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787873Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: January 16, 2020Date of Patent: October 17, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Patent number: 11732052Abstract: Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.Type: GrantFiled: April 2, 2020Date of Patent: August 22, 2023Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Patent number: 11547748Abstract: The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, ?? T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described.Type: GrantFiled: June 30, 2017Date of Patent: January 10, 2023Inventors: Christian Klein, Claudio Sustmann, Gerhard Niederfellner, Martina Geiger, Stefan Endres, Sebastian Kobold
-
Publication number: 20220017640Abstract: The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies.Type: ApplicationFiled: November 6, 2020Publication date: January 20, 2022Applicant: HOFFMANN-LA ROCHE INC.Inventors: Ulrich BRINKMANN, Rebecca CROASDALE, Silke METZ, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
-
Patent number: 10808038Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.Type: GrantFiled: November 10, 2016Date of Patent: October 20, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
-
Publication number: 20200317806Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an \JD antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor M specific antigen naturally occurring on the surface of a minor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.Type: ApplicationFiled: April 2, 2020Publication date: October 8, 2020Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Patent number: 10793621Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.Type: GrantFiled: April 24, 2018Date of Patent: October 6, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
-
Publication number: 20200291131Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: January 16, 2020Publication date: September 17, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Patent number: 10633451Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.Type: GrantFiled: January 24, 2013Date of Patent: April 28, 2020Assignees: Hoffmann-La Roche Inc., Ludwig-Maximillians-Universität MünchenInventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Publication number: 20200108154Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: ApplicationFiled: August 28, 2019Publication date: April 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jen FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
-
Patent number: 10611825Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: June 12, 2017Date of Patent: April 7, 2020Assignee: HOFFMANN LA-ROCHE INC.Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
-
Patent number: 10584178Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: June 17, 2016Date of Patent: March 10, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Publication number: 20200062826Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.Type: ApplicationFiled: May 15, 2019Publication date: February 27, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich BRINKMANN, Rebecca CROASDALE, Eike HOFFMANN, Christian KLEIN, Ekkehard MOESSNER, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
-
Patent number: 10434184Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: GrantFiled: April 27, 2018Date of Patent: October 8, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Sebastian Fenn, Jens Fischer, Thomas Friess, Sabine Imhof-Jung, Ben-Fillippo Krippendorff, Christian Schantz, Tilman Schlothauer, Claudio Sustmann, Barbara Weiser, Adrian Zwick
-
Publication number: 20190216908Abstract: The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, ?? T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described.Type: ApplicationFiled: June 30, 2017Publication date: July 18, 2019Inventors: Christian Klein, Claudio Sustmann, Gerhard Niederfellner, Martina Geiger, Stefan Endres, Sebastian Kobold
-
Publication number: 20180312573Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.Type: ApplicationFiled: April 24, 2018Publication date: November 1, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg-Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN
-
Publication number: 20180311371Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: ApplicationFiled: April 27, 2018Publication date: November 1, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
-
Publication number: 20180282399Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.Type: ApplicationFiled: December 28, 2017Publication date: October 4, 2018Inventors: Ulrich BRINKMANN, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
-
Patent number: 9982036Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.Type: GrantFiled: February 27, 2012Date of Patent: May 29, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
-
Patent number: 9890204Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.Type: GrantFiled: August 7, 2012Date of Patent: February 13, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana